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Abstract
Despite using modern microbiological diagnostic approaches, the aetiological
agents of pneumonia remain unidentified in about 50% of cases. Some bacteria
that grow poorly or not at all in axenic media used in routine clinical bacteriology
laboratory but which can develop inside amoebae may be the agents of these lower
respiratory tract infections (RTIs) of unexplained aetiology. Such amoebae-
resisting bacteria, which coevolved with amoebae to resist their microbicidal
machinery, may have developed virulence traits that help them survive within
human macrophages, i.e. the first line of innate immune defence in the lung. We
review here the current evidence for the emerging pathogenic role of various
amoebae-resisting microorganisms as agents of RTIs in humans. Specifically, we
discuss the emerging pathogenic roles of Legionella-like amoebal pathogens, novel
Chlamydiae (Parachlamydia acanthamoebae, Simkania negevensis), waterborne
mycobacteria and Bradyrhizobiaceae (Bosea and Afipia spp.).
Introduction
Despite advances in antibiotic therapy, pneumonia remains
one of the leading infectious causes of death in developed
countries and a major cause of morbidity, especially in the
elderly population and among patients with chronic under-
lying diseases (Mandell et al., 2007). Although a broad
spectrum of microbial pathogens have been recognized as
causal agents of respiratory tract infections (RTIs), the
offending microorganism remains unknown in about half
of the cases of community-acquired pneumonia (CAP)
(Bochud et al., 2001; Echols et al., 2008), and three quarters
of the cases of nosocomial pneumonia (Costa et al., 2001).
Microorganisms causing pneumonia may be acquired
from respiratory droplets through human-to-human con-
tact or from aerosolized particles from an animal or
environmental reservoir. The epidemiology of RTI thus
strongly depends on the interactions between humans and
their ecosystem and evolves according to environmental
changes due to human activities, climatic or ecological
perturbations. Pandemics of influenza or the emergence of
new respiratory diseases such as severe acute respiratory
syndrome are dramatic illustrations of these phenomena. To
some extent, agents of pneumonia have been identified in
the context of outbreaks or case series occurring in a
particular setting. For instance, psittacosis (parrot fever)
was described for the first time in seven individuals exposed
to pet birds in Switzerland in the 19th century (Ritter, 1880).
More recently, the epidemics of severe pneumonia affecting
war veterans in a hotel in Philadelphia in 1976 led to the
discovery of the fastidious gram-negative rod Legionella
pneumophila as a causal agent of respiratory diseases (Fraser
et al., 1977; McDade et al., 1977). In this latter situation,
water was found to be the source of contamination. Rowbo-
tham (1980, 1983) then demonstrated that L. pneumophila
may multiply within free-living amoebae and hypothesized
that these protists may represent a reservoir for these
intracellular bacteria.
Free-living amoebae live in water, soil and at the water–air
interface. As they generally use bacteria as their main
nutritional source, they are especially present in large
quantities in sediments and biofilms (Rodriguez-Zaragoza,
1994). Thus, humans have been increasingly exposed to
amoebae and to their related bacterial pathogens with the
progressive development of various modern man-made
water systems such as water-treatment plants, cooling
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towers, air conditioners, humidifiers, spas and swimming
pools (Rodriguez-Zaragoza, 1994; Greub & Raoult, 2004;
Pagnier et al., 2009a). Apart from L. pneumophila, which has
mainly been recognized due to the dramatic importance of
the Philadelphia outbreak, many other bacteria that resist
the phagocytic amoebae may also use these protists as
widespread reservoirs and may have acquired virulence
traits promoting their resistance to macrophages. Interest-
ingly, some of these amoebae-resisting bacteria have also
been discovered during outbreaks of RTI (Herwaldt et al.,
1984; Birtles et al., 1997). Indeed, given their intracellular
lifestyle, they either do not grow or only poorly grow in
conventional axenic media. It is important that the micro-
biology community be well aware of these new emerging
human agents of pneumonia and develop new diagnostic
tools for their identification. Amoebal coculture and amoe-
bal enrichment coupled with detection of potential intra-
amoebal bacteria have been demonstrated to be largely
successful in identifying a large biodiversity of new patho-
gens from patients (Greub et al., 2004b; Thomas et al., 2006;
Corsaro et al., 2009; Pagnier et al., 2009a, b).
In this review, we intend to present the current evidence
of the role of various amoebae-resisting bacteria as agents of
RTI in humans. More specifically, we will discuss the likely
role of Legionella-like amoebal pathogens (LLAPs), novel
Chlamydiae (Parachlamydia acanthamoebae, Simkania nege-
vensis), waterborne mycobacteria and Bradyrhizobiaceae
(Bosea and Afipia spp.).
Diagnostic tools for the identification of
amoebae-resisting bacteria
For a better characterization of the microbial biodiversity,
various molecular approaches are available, including a
coupled cloning and sequencing approach, and metage-
nomics using new pyrosequencing techniques such as the
454 and Solexa/Illumina technologies. However, such se-
quence-based ecological studies do not provide the strains
for subsequent studies, and consequently culture-based
ecological studies are of equal if not greater importance.
However, most culture-based studies are biased towards
bacteria able to grow efficiently on different axenic media,
broths and/or agar plates, and approaches that selectively
amplify amoebae-resisting bacteria may be useful. Two main
approaches, amoebal coculture and amoebal enrichment,
have been applied so far to recover amoebae-resisting
bacteria in culture (Fig. 1). Amoebal coculture is a cell
culture method in which axenic amoebae are used as a host
cell culture, whereas amoebal enrichment uses an enteric
bacterium such as Escherichia coli as a food source for
amoebae that are potentially present in the investigated
sample. Once isolated by amoebal enrichment, the amoebae
may then be studied for the possible presence of intra-
amoebal microorganisms. Both approaches have been suc-
cessfully used in recent years to uncover a variety of
amoebae-resisting microorganisms from both environmen-
tal and clinical samples (Adekambi et al., 2004; Greub et al.,
2004b; Thomas et al., 2006, 2008; Loret et al., 2008; Corsaro
et al., 2009; Pagnier et al., 2009b).
Understanding the pathogenic role of
amoebae-resisting bacteria: a
comprehensive model approach
The availability of a bacterial strain growing in amoebae
allows its pathogenic potential to be tested, for instance as
an agent of pneumonia, using the comprehensive approach
that has been applied to P. acanthamoebae (Greub, 2009).
This global strategy includes (1) testing the permissiveness
of lung fibroblasts, pneumocytes and alveolar macrophages
to the new bacterial species; (2) developing diagnostic tools
(serology, antigen-detection assays, PCR and immunohisto-
chemistry) to study patients with and without lower RTIs;
and (3) investigating the pathogenic role of some selected
species in an animal model of pneumonia. For species that
emerge as new pathogens or exhibit very peculiar interesting
biological phenotypes, the availability of a given strain also
allows better understanding of the biology of the species
involved, using functional genomics, proteomics and cell
biology.
Amoebal pathogens as causal agents of
pneumonia: clinical evidence
Legionella species
Legionella pneumophila
The potential role of water systems as a reservoir of human
respiratory diseases was recognized for the first time when
L. pneumophila was identified as the causal agent of an
outbreak of pneumonia in Philadelphia in 1976 (Fraser
et al., 1977; McDade et al., 1977). This bacterium is wide-
spread in our aquatic environment including man-made
water systems and is one of the first examples of amoebae-
resisting bacteria that has been described (Rowbotham, 1980,
1983). It is estimated to account for 2–7% of all cases of CAP
affecting both immunocompromised and immunocompe-
tent hosts (Doebbeling & Wenzel, 1987; Marrie et al., 1989;
Fang et al., 1990a; Woodhead, 2002). Nosocomial outbreaks
of Legionnaires’ disease are also frequently reported and may
result from bronchoaspiration of contaminated potable
water rather than inhalation of aerosolized particules (Blatt
et al., 1993; Sabria & Yu, 2002). In addition to potentially
severe respiratory diseases, legionellosis may present as a
flu-like syndrome called pontiac fever, which may be
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Fig. 1. Culture-based approaches that may be used to selectively grow amoebae-resisting microorganisms. (a) Amoebal coculture is a cell culture
approach that uses amoebae as cell background and that can be used to isolate strict intracellular bacteria starting directly from clinical and/or
environmental samples or by inoculation of free-living amoebae potentially containing amoebal pathogens or endosymbionts. Screening may then be
achieved with various stainings and/or by PCRs. Subcultures on fresh amoebae in presence/absence of different antibiotics may help in isolating a given
strain from heavily contaminated environmental samples. (b) Free-living amoebae may be isolated by amoebal enrichment, which consists in the
inoculation of clinical and/or environmental samples on non-nutritive agar plates previously seeded with Escherichia coli and/or Enterobacter cloacae,
which serve as a food source for the amoebae potentially present in the investigated sample. Once inoculated, agar plates can be screened daily for the
presence of an amoebal migration front and, when positive, subcultured on new non-nutritive agar. Amoebae can then be screened for the presence of
amoebae-resisting microorganisms by amoebal coculture and or molecular approaches.
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misdiagnosed as a viral infection and whose incidence is
possibly underestimated (Doebbeling & Wenzel, 1987).
Legionella pneumophila is a fastidious gram-negative rod
which is rarely detected by examination of gram stains of
clinical samples and which needs buffered charcoal yeast
extract (BCYE) agar to be grown. The availability of a
urinary-specific antigen test for the detection of L. pneumo-
phila serogroup 1, which accounts for about 85–90% of
legionellosis in Europe and America, allows a rapid diag-
nosis of the disease. This test, in combination with cultures,
exhibits an overall good sensitivity and specificity and its
widespread use has improved the identification of Legionella
pneumonia in hospitalized patients (Waterer et al., 2001).
Molecular diagnostic tools have shown promising results
but these methods lack standardization and their availability
is limited (Waterer et al., 2001; Murdoch, 2003). The actual
role of L. pneumophila in less severe pneumonia in the
community as well as the incidence of respiratory diseases
attributed to other Legionella species thus remain difficult to
estimate (Waterer et al., 2001; Murdoch, 2003).
Legionella species other than L. pneumophila
Since the discovery of L. pneumophila, about 45 other
Legionella species have been identified (Benson & Fields,
1998). These species share the same aquatic environment as
L. pneumophila and about half of them have been associated
with respiratory infections in humans (Table 1) (Muder &
Yu, 2002; Roig et al., 2003). However, only a limited number
of species seems to be relevant pathogens, whereas the others
have been identified as the cause of pneumonia in anecdotal
case reports. In a multinational survey, they have been
estimated to account for 5–10% of legionellosis (Benin
et al., 2002; Yu et al., 2002). The distribution of Legionella
spp. is variable around the world: for instance, Legionella
longbeachae is responsible for as many as 30% cases of
Legionella diseases in Australia and New Zealand, whereas
it accounts for only 3–4% of cases on the European and
American continents (Yu et al., 2002). Legionella bozemanii,
Legionella micdadei, Legionella dumoffii, Legionella anisa and
Legionella feelei may account for most of the 1–5% remain-
ing cases of Legionnaires’ diseases (Fang et al., 1989;
McNally et al., 2000; Benin et al., 2002; Muder & Yu, 2002;
Yu et al., 2002). In contrast to L. pneumophila infections,
pulmonary diseases attributed to other Legionella spp. have
been mainly reported in a nosocomial context affecting
immunocompromised patients such as haematopoietic or
solid organ transplant recipients, patients under long-term
corticoid therapy or splenectomized patients (Muder et al.,
1983; Fang et al., 1989; Muder & Yu, 2002). With the
exception of L. longbeachae, other Legionella spp. are rarely
involved in CAP, although community outbreaks of pontiac
fever have also been reported with L. anisa, L. micdadei,
L. feelei and Legionella sainthelensi (Herwaldt et al., 1984;
Goldberg et al., 1989; Fenstersheib et al., 1990; Loeb et al.,
1999).
Most Legionella species grow on BCYE agar media, but
specific cultures for Legionella are not routinely performed
in cases of CAP. Moreover, these media usually contain
antibiotics for the selection of L. pneumophila that may
inhibit the growth of some other Legionella species. The
urinary antigen test does not detect species other than L.
pneumophila serogroup 1, and PCR methods are as yet not
widely used. For these reasons, Legionella spp. other than L.
pneumophila are rarely identified as causal agents of infec-
tions and their role in the epidemiology of community- and
hospital-acquired pneumonia has not been assessed pre-
cisely. The fact that these species exhibit a variable ability to
infect and proliferate within amoebae may partly explain
why they are less frequently involved in RTIs compared with
L. pneumophila (Neumeister et al., 1997; Gao et al., 1999).
LLAPs
Historically, the term Legionella-like amoebal pathogens was
introduced to designate obligate intracellular parasites of free-
living amoebae which were closely related to the legionellae
(Fig. 2) and which, unlike other Legionella spp., exhibited
little or no growth on conventional bacteriological media
such as BCYE agar (Rowbotham, 1986; Greub & Raoult,
2004). Most strains were originally isolated from water
supplies during investigations of individual cases or outbreaks
of Legionnaires’ disease (Adeleke et al., 1996; Birtles et al.,
1996). Because of their limited ability to grow in culture,
these bacteria could not be completely characterized and were
initially designated by numbers (e.g. LLAP-1–14). The first
isolation of an LLAP (LLAP-3) in a clinical specimen was
reported in 1991 using amoebal enrichment of the sputum of
a patient with pneumonia who exhibited seroconversion
against this strain (Fry et al., 1991). Phylogenetic analyses
subsequently allowed its classification in the species Legionella
lytica (Birtles et al., 1996), whereas other LLAP strains were
characterized and assigned to new species of Legionella
(Legionella drozanskii, Legionella rowbothamii, Legionella fal-
lonii, Legionella drancourtii) (Adeleke et al., 1996, 2001; La
Scola et al., 2004). The term of LLAPs thus has been retained
for historical reasons, as most of these species have now been
recognized to belong phylogenetically to the Legionella genus.
Moreover, most of them are currently able to grow on BCYE
agar because of the improvement in the quality of media and
possibly because of a progressive adaptation by successive
subcultures on amoebae.
The pathogenic role of LLAPs has been investigated in
two series of patients suggesting that these fastidious bacter-
ia may be a cause of pneumonia in some cases (Table 1)
(McNally et al., 2000; Marrie et al., 2001). A French study
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Table 1. Pathogenic role of Legionella spp. in pneumonia
Legionella species Pathogenic role in pneumonia References
L. pneumophila 2–7% of community-acquired pneumonia (8% of those
requiring ICU), 5% of nosocomial pneumonia
Doebbeling & Wenzel (1987), Marrie et al. (1989), Fang
et al. (1990a), Woodhead (2002)
Most frequent cause of Legionella pneumonia (91.5%) Yu et al. (2002)
L. longbeachae Second cause of Legionella pneumonia worldwide
(3.9%)
Yu et al. (2002)
Frequent cause of potentially severe community-acquired
pneumonia in Australia, New Zealand and South East
Asia
Grove et al. (2002), Yu et al. (2002), Phares et al. (2007)
Few cases reported in Europe or United States McKinney et al. (1981), Yu et al. (2002), McClelland et al.
(2004), Kumpers et al. (2008)
L. bozemanii Third cause of community-acquired Legionella
pneumonia (2.4%)
Fang et al. (1989), McNally et al. (2000), Yu et al. (2002)
Cause of severe pneumonia in immunocompromised
patients (frequent complications: empyema, cavitation)
Fang et al. (1989), Swinburn et al. (1988), Taylor &
Albrecht (1995), Harris et al. (1998), Muder & Yu (2002)
L. micdadei Cause of life-threatening pneumonia in
immunocompromised patients
Myerowitz et al. (1979), Muder et al. (1983), Fang et al.
(1987), Doebbeling et al. (1989), Muder & Yu (2002)
Purulent pneumonia or pulmonary abscesses in solid-
organ transplant recipients
Myerowitz et al. (1979), Rogers et al. (1979), Mehta et al.
(1983), Ernst et al. (1998), Knirsch et al. (2000)
L. anisa Rare cause of community-acquired or nosocomial
pneumonia
McNally et al. (2000), Yu et al. (2002), La Scola et al.
(2003b), Doleans et al. (2004)
Identified as the cause of an outbreak of pontiac fever in
California
Fenstersheib et al. (1990)
L dumoffii Some cases of pneumonia reported mainly in
immunocompromised patients
Fang et al. (1990b), Murdoch & Chambers (2000), Muder
& Yu (2002), Yu et al. (2002)
L. feeleii About 10 cases of pneumonia reported in the literature
(75% in immunocompromised patients)
Lee et al. (2009)
One outbreak of pontiac fever in an automobile plant Herwaldt et al. (1984)
L. jordanis Subacute or chronic respiratory infection with
constitutional symptoms (rare cases described)
Thacker et al. (1988b), Vinh et al. (2007)
L. sainthelensi Two outbreaks of respiratory infections in nursing homes
(Canada)
Loeb et al. (1999)
L. maceachernii Case reports of pneumonia in immunocompromised
patients
Wilkinson et al. (1985a), Thomas et al. (1992), Dumoff
et al. (2004), van Dam et al. (2006)
L. gormanii Case reports of pneumonia in immunocompromised
patients
Griffith et al. (1988), Ephros et al. (1989), Towns et al.
(1994)
L. wadsworthii Case reports of pneumonia in immunocompromised
patients
Edelstein et al. (1982), Yu et al. (2002)
L. cincinnatiensis Case reports of pneumonia in renal transplant recipients
or haemodialysis patient
Thacker et al. (1988a), Jernigan et al. (1994)
L. tucsonensis Case reports of pneumonia in immunocompromised
patients
Thacker et al. (1989), Doleans et al. (2004)
L. oakridgensis 3 cases of pneumonia observed in patients with
connective tissue diseases
Tang et al. (1985), Lo Presti et al. (2000)
L. parisiensis One case report of pneumonia in a liver transplant
recipient
Lo Presti et al. (1997)
L. lansingensis One case report of pneumonia in a patient with chronic
lymphocytic leukaemia
Thacker et al. (1992)
L. hackeliae One case report of pneumonia immunocompromised
patient
Wilkinson et al. (1985b)
L. lytica (LLAP 3, 7 and 9) Seroconversion observed in cases of community-acquired
pneumonia
Fry et al. (1991), McNally et al. (2000)
L. drancourtii (LLAP 4 and 12) Seroprevalence study suggesting a pathogenic role Marrie et al. (2001)
L. fallonii (LLAP 10) Seroprevalence study suggesting a pathogenic role McNally et al. (2000)
L. rowbothamii (LLAP 6) Seroprevalence study suggesting a pathogenic role McNally et al. (2000)
L. drozanskii (LLAP 1) Seroprevalence study suggesting a pathogenic role McNally et al. (2000), Marrie et al. (2001)
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reported serological evidence for recent infections with
LLAP in 1.4% of CAP (Marrie et al., 2001). Most of them
were attributed to LLAP-4 (L. drancourtii). An alternative
potential pathogen was, however, isolated in about half of
these cases. Similarly, a significant rise in antibodies against
LLAP-1, -3, -6, -9 and -10 was reported in 7% of patients
with CAP of unknown aetiology in a North American series
(McNally et al., 2000). Data from other parts of the world or
other subsets of population are lacking, although the
ubiquity and biodiversity of Legionella spp., including
LLAPs, in water systems has been reported worldwide
(Thomas et al., 2006; Diederen et al., 2007; Wery et al.,
2008; Hsu et al., 2009). The role of LLAPs in human diseases
is difficult to assess, as their pathogenic role was suggested
only by serological tests in relatively few cases, and in the
absence of direct microbiological documentation by other
diagnostic tools such as culture or molecular methods.
Moreover, in vitro studies or animal models supporting
their pathogenicity are currently lacking.
Chlamydia-related bacteria
Molecular and phylogenetic studies have recently revealed a
rich diversity of microorganisms within the order Chlamy-
diales and allowed the identification of new families distinct
from the well-known Chlamydiaceae (Everett et al., 1999;
Corsaro & Greub, 2006; Greub, 2009). The term ‘Chlamy-
dia-like organisms’, ‘novel Chlamydiae’, ‘Chlamydia-related
bacteria’ or ‘amoebae-resistant Chlamydiae’ have been used
to designate these strict intracellular bacteria that may infect
and survive within free-living amoebae. Growing evidence
suggests that some of them may be the cause of RTIs in
humans (Friedman et al., 2003; Corsaro & Greub, 2006;
Greub, 2009).
Simkaniaceae
Simkania negevensis, formerly called microorganism ‘Z’ or
‘Simkania Z’, is the member of these Chlamydia-like organ-
isms whose implication in RTIs has been most extensively
studied. This bacterium may easily grow within the
Acanthamoeba amoeba (Fig. 3) and may also use free-living
amoebae as a widespread environmental reservoir. Simkania
negevensis was first described in 1993 as a cell culture
contaminant of unknown origin exhibiting a typical two-
stage developmental cycle, with infectious elementary
bodies and replicative reticulate bodies (Fig. 4), but differing
significantly from Chlamydiaceae (Kahane et al., 1993). Its
seroprevalence in the population displays important varia-
tions around the world, having been reported to be as high
as 55–80% in Israel and only 4% in Japan (Friedman et al.,
1999, 2006; Johnsen et al., 2005; Yamaguchi et al., 2005).
These differences may be partially due to the respective
sensitivity and specificity of the serological approaches used
and to the cut-off defining positivity. The involvement of
S. negevensis in RTIs has been investigated in several large
cohorts of patients in Europe, the Middle East and America
using serological or molecular diagnostic methods (Table 2)
(Kahane et al., 1998; Lieberman et al., 2002, 1997; Greenberg
et al., 2003; Kumar et al., 2005; Friedman et al., 2006; Fasoli
et al., 2008; Heiskanen-Kosma et al., 2008; Nascimento-
Carvalho et al., 2009). Some of these analyses reported an
association with CAP, exacerbations of chronic obstructive
Fig. 2. Legionella drancourtii, i.e. LLAP-12, within Acanthamoeba cas-
tellannii as seen by gram staining (a) and Diff-Quick staining (modified
May–Gru¨nwald Giemsa) (b), respectively. Infected amoebae, which
contain numerous rod-shaped bacteria, are circled by a dotted line.
Microscopy performed 24 h postinfection at a low MOI of about 1/10;
 1000 magnification.
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pulmonary diseases or bronchiolitis in adults and children
(Kahane et al., 1998; Lieberman et al., 2002, 1997; Friedman
et al., 2003, 2006; Greenberg et al., 2003; Fasoli et al., 2008;
Heiskanen-Kosma et al., 2008; Nascimento-Carvalho et al.,
2009). The importance of this bacterium as a causal agent of
CAP is, however, difficult to evaluate and seems relatively
marginal (o 2% of all aetiologies) in view of these results. Its
incidence may be higher in some populations or ethnic
groups where a high seroprevalence of S. negevensis has been
documented, for example in the Middle East (Bedouins)
(Kahane et al., 1998; Friedman et al., 1999) or Northern
Canada (Inuits) (Greenberg et al., 2003), whereas it remains
to be determined in many other parts of the world. A study
carried out in Brooklyn (NY) deserves mention as it did not
identify any association with respiratory diseases despite a
Fig. 3. Simkania negevensis within Acanthamoeba castellannii, as seen
by electron microscopy 24 h postinfection. Please note (a) the presence
of several dividing reticulate bodies (arrows). (b) An elementary body in
the process of being phagocytized (arrow). Magnification  7000 and
10 000, respectively. Scale bar = 2 mm.
Fig. 4. The two developmental stages of Simkania negevensis: the reticulate
body, i.e. the metabolically active dividing stage (a) and the elementary body,
i.e. the infectious stage (b). Simkania negevensis may also infrequently
exhibit a third stage, the crescent body (initially reported for Parachlamydia
acanthamoebae), which may be seen on some electron microscopy prepara-
tions (c). Electron micrographs: magnification  70 000; Scale bar= 0.2mm.
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high prevalence (23.5%) of antibody titers against S. nege-
vensis among adults and children in this population, sug-
gesting that these Chlamydia-related bacteria are simple
colonizers (Kumar et al., 2005). Thus, thorough evaluation
of the pathogenic role of S. negevensis is warranted, as most
studies did not include a control group, and among the few
studies with a control group, most failed to demonstrate a
significant correlation with lower RTIs (Table 2).
The implication of S. negevensis in other respiratory
diseases, such as chronic cough or asthma, has also been
investigated and could not be demonstrated conclusively
(Johnsen et al., 2005; Kumar et al., 2005; Korppi et al., 2006).
In one study, S. negevensis was detected by a PCR method in
bronchoalveolar lavage samples of lung transplant recipients
with a surprisingly high prevalence (97.5%, when compared
with only 14.1% in other solid-organ transplant recipients;
Po 0.0001) (Husain et al., 2007). Many of these patients did
not have documented pneumonia and the pathogenic role
of S. negevensis in this context thus remains unclear. The
authors of this study postulated a possible role in acute graft
rejection, although the analysis was underpowered to reach
statistical significance. Like other Chlamydia-related organ-
isms, S. negevensis may infect free-living amoebae such as
Acanthamoeba which are widespread in water, including
hospital water supplies (La Scola et al., 2002; Thomas et al.,
2006). Hospitalized patients exposed to aerosolized parti-
cles, such as those undergoing mechanical ventilation, may
thus be colonized or infected by these intracellular bacteria,
whose pathogenic role in this setting has been poorly
investigated (La Scola et al., 2002). However, it is worth
noting that in vitro studies of the pathogenesis of
S. negevensis have demonstrated its ability to infect human
macrophages and to induce a host cell inflammatory re-
sponse, supporting its potential ability to cause human
infections and the need for further clinical investigations
(Kahane et al., 2008, 2007).
Parachlamydiaceae
This family has drawn increasing attention in the last decade
because of the potential pathogenicity of its first recognized
member, P. acanthamoebae, which was identified as the
cause of an outbreak of fever of undetermined origin
occurring in Vermont in 1989 (Birtles et al., 1997). An
amoeba of the Acanthamoeba genus was isolated from the
water of a humidifier and was subsequently shown to be
infected with a gram-negative bacterium termed Hall’s
coccus. This organism was characterized by comparative
sequence analyses (Birtles et al., 1997) and was found to be
similar to a Chlamydia-like endoparasite of Acanthamoeba
(strain Bn9) previously identified in the nasal mucosa of
healthy subjects (Amann et al., 1997). Hall’s coccus and
strain Bn9 were subsequently assigned to the species
P. acanthamoebae within the Chlamydiales order (Everett
Table 2. Simkania negevensis as causal agents of pneumonia: review of the literature
Population (country) and
number of patients Disease Diagnostic method
Positive
results
P value
(if controls)
Recent infection
and no alternative
pathogen References
Adults (Israel) 308 CAP Serology (IgG, IgA) 112 (37%) No control 4 (1.3%) Lieberman et al. (1997)
Infants (Israel) 239 Bronchiolitis Culture and/or PCR
(NP swabs)
60 (25%) Po 0.001 38 (16%) Kahane et al. (1998)
Adults (Israel) 190 COPD
exacerbation
Serology (IgG, IgA) 120 (63%) Not significant 1 (0.5%) Lieberman et al. (2002)
Infants (Canada) 22 Bronchiolitis PCR (NP swabs) 14 (64%) No control 2 (9%) Greenberg et al. (2003)
Adults/children (USA) 188 Bronchiolitis,
Pneumonia
Serology (IgG) (n= 69) 14 (18%) Not significant NA Kumar et al. (2005)
Asthma PCR (NPl swabs)
(n= 169)
29 (17%) Not significant NA
Adults (UK) 29 RTI Serology (IgG) 18 (62%) Not significant NA Friedman et al. (2006)
Serology (IgA) 5 (17%) P= 0.004 NA
Children (UK) 222 Bronchiolitis Culture and/or PCR
(NP swabs)
111 (50%) No control NA Friedman et al. (2006)
Children (Italy) 101 CAP Serology (IgM, IgG) 20–30% No control 2 (2%) Fasoli et al. (2008)
Children (Finland) 174 CAP Serology (IgM) 18 (10%) No control 6 (3.4%) Heiskanen-Kosma et al.
(2008)
Children (Brazil) 184 CAP Serology (IgM, IgG) 3 (1.6%) No control 1 (0.5%) Nascimento-Carvalho
et al. (2009)
Recent infection was defined as: serological evidence for recent infection (positive IgM or significant increase between initial and convalescent IgG
titres) or positive PCR result during the course of infection.
COPD, chronic obstructive pulmonary disease; NA, data not available.
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et al., 1999). The ability of P. acanthamoebae to replicate
within free-living amoebae of the genus Acanthamoeba has
been well described and is shown in Fig. 5.
Further studies reported a significantly higher rate of
seropositivity for P. acanthamoebae among patients with
RTIs when compared with healthy controls (Marrie et al.,
2001; Greub et al., 2003b; Greub, 2009). However, serologi-
cal evidence for a recent infection in the absence of other
potential documented pathogens could be assessed in only a
few cases, suggesting that these bacteria may account for
o 1% of CAP (Marrie et al., 2001; Greub et al., 2003a) and
about 8% of ventilator-associated pneumonia (VAP) (Greub
et al., 2003b) (Table 3). More recently, the use of a specific
real-time PCR allowed the identification of P. acanthamoe-
bae or a related species as the only potential pathogen in as
many as 13% of children with bronchiolitis, suggesting that
the pathogenic role of Parachlamydiaceae may be under-
estimated in some clinical settings (Casson et al., 2008c).
Moreover, experimental models have demonstrated the
ability of P. acanthamoebae to enter and replicate within
human macrophages (Greub et al., 2003c, 2005) and pneu-
mocytes (Casson et al., 2006) and to cause pneumonia in
mice (Casson et al., 2008a). Molecular analyses also allowed
the identification of other members of the family Parachla-
mydiaceae in respiratory samples of some cases of pneumo-
nia (Corsaro et al., 2002; Casson et al., 2008b; Haider et al.,
2008). Protochlamydia naegleriophila was detected as the
unique potential pathogen in an immunocompromised
patient with lung infiltrate (Casson et al., 2008b) and one
case of CAP possibly attributed to Protochlamydia amoebo-
phila has been reported (Haider et al., 2008) (Table 3).
Further clinical studies are warranted to better define the
pathogenicity and the epidemiology of P. acanthamoebae
and other Parachlamydiaceae among the causal agents of
RTIs.
Other Chlamydia-related organisms
Culture- and molecular-based studies on human, animal or
environmental samples have led to the identification of
many new Chlamydia-related organisms, attesting to the
rich biodiversity within the order Chlamydiales (Greub,
2009). New strains have been identified and assigned to
different families according to phylogenetic analyses,
whereas others failed to grow in culture and could only be
described by comparative sequence analyses. Some of them
have been documented by PCR methods in human respira-
tory samples, but their pathogenic role remains unknown
(Ossewaarde & Meijer, 1999; Corsaro et al., 2001; Haider
et al., 2008). Using a molecular approach targeting the 16S
rRNA gene (a conserved gene in the genome of all bacteria),
Haider et al. (2008) recently found DNA of Chlamydia-
related organisms in about 1% of adult patients with CAP,
Fig. 5. Parachlamydia acanthamoebae within Acanthamoeba castellan-
nii, as seen by gram staining (a), Diff-Quick staining (modified
May–Gru¨nwald Giemsa) (b), and immunofluorescence (c), respectively.
Microscopy performed 24 h postinfection at an MOI of about  10. (a)
Note that elementary bodies are generally gram-positive, whereas the
reticulate bodies are gram-negative. (c) The cell wall of P. acanthamoe-
bae (in green) was stained with mice polyclonal anti-Parachlamydia
antibodies whereas the amoeba was stained with concanavalin A.
Magnification  1000.
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including Waddlia chondrophila (Family: Waddliaceae) and
Rhabdochlamydia porcellionis (Family: Rhabdochlamydia-
ceae) (Haider et al., 2008). No sequence related to
S. negevensis or P. acanthamoebae was detected in this series.
The presence of Rhabdochlamydia spp. in respiratory samples
of premature neonates has been recently reported, although
their role as a causal agent of pneumonia or other systemic
infections could not be assessed (Lamoth et al., 2009). It is
thus difficult to estimate which proportion of RTIs in
humans are caused by these Chlamydia-like organisms.
Waterborne mycobacteria
Nontuberculous mycobacteria are associated with dissemi-
nated or pulmonary infection in immunocompromised
patients and may be the cause of various infectious diseases
such as lymphadenitis, cutaneous infections or, rarely,
pneumonia in the immunocompetent host (Falkinham,
1996). Among them, the Mycobacterium avium complex
and Mycobacterium kansasii are the species most frequently
associated with respiratory tract colonization or true infec-
tion in both immunocompromised and immunocompetent
patients (Falkinham, 1996; Field & Cowie, 2006). Mycobac-
terium xenopi, Mycobacterium fortuitum, Mycobacterium
simae, Mycobacterium abscessus, Mycobacterium chelonae,
Mycobacterium gordonae and Mycobacterium malmoense are
other recognized agents of pneumonia, occurring mainly in
immunocompromised hosts or patients with underlying
pulmonary diseases (Table 4) (Field & Cowie, 2006).
The genusMycobacterium has been considerably enriched
with the discovery of a large number of new species during
the last decades (Primm et al., 2004). These mycobacterial
species have been isolated from water sources, soil, air,
human or animal reservoirs, reflecting their ubiquity in the
environment (Falkinham, 2002; Primm et al., 2004). Natural
fresh or salt waters, such as lakes, rivers, swamps, estuaries
or marine streams, are common habitats of opportunistic
mycobacteria. Their resistance to chlorine and most disin-
fectants used for water treatment as well as their ability to
survive despite low nutrient levels, low oxygen content or
extreme temperatures allow them to colonize drinking water
supplies, cooling towers, swimming pools and other recrea-
tional water systems (Falkinham, 2002; Black & Berk, 2003;
Pagnier et al., 2009b). Their selection by surface disinfec-
tants may also promote their widespread occurrence in the
hospital environment. Moreover, these pathogens are able to
form biofilms and to colonize medical devices such as
bronchoscopes (Wallace et al., 1998; Falkinham, 2002).
Nontuberculous waterborne mycobacteria are frequently
isolated from clinical specimens (Martin-Casabona et al.,
2004) and nosocomial outbreaks have been reported
(Wallace et al., 1998; Phillips & von Reyn, 2001). In most
cases, the presence of such microorganisms in the respira-
tory tract reflects transient colonization. However, several
cases or small outbreaks of hospital-acquired pneumonia
have been ascribed to M. xenopi, M. chelonae and M. simae
(Wallace et al., 1998; Phillips & von Reyn, 2001; Conger
et al., 2004). Community-acquired respiratory diseases such
Table 3. Parachlamydiaceae as causal agents of pneumonia: review of the literature
Genus/species
Population (country)
and number of patients Disease Diagnostic method
Positive
results
P value
(if controls)
Recent
infection
and no
alternative
pathogen References
Parachlamydia
acanthamoebae
Adults (Canada) 371 CAP Serology (IgM, IgG) 8 (2.2%) Po 0.01 1 (0.3%) Marrie et al. (2001)
Adults/children (France) 1200 Pneumonia PCR (BAL) 1 (0.1%) No control 1 (0.1%) Greub et al. (2003a)
Adults (France) 37 VAP Serology (IgM, IgG) 5 (13.5%) Po 0.001 3 (8.1%) Greub et al.
(2003b)
ICU adults (France) 210 Pneumonia PCR and culture (BAL),
serology (IgM, IgG)
3 (1.4%) No control 1 (0.5%) Berger et al. (2006)
Children (Switzerland) 39 Bronchiolitis PCR (NP swabs) 6 (15%) No control 5 (13%) Casson et al.
(2008c)
Protochlamydia
amoebophila
Adults (Austria) 387 CAP PCR (respiratory
samples)
1 (0.3%) No control 1 (0.3%) Haider et al. (2008)
Protochlamydia
naegleriophila
Adults/children (Switzerland)
65
Pneumonia PCR (BAL) 1 (1.5%) Not
significant
1 (1.5%) Casson et al.
(2008b)
Other
Parachlamydia
spp. (unclassified)
Adults/children (France/Italy)
170
Pneumonia PCR (respiratory
samples)
2 (1.2%) No control NA Corsaro et al.
(2002)
Recent infection was defined as: serological evidence for recent infection (positive IgM or significant increase between initial and convalescent IgG
titres) or positive PCR result during the course of infection.
BAL, bronchoalveolar lavage fluid; NA, data not available.
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as hypersensitivity pneumonitis and even cases of true
pneumonia have been reported in healthy individuals ex-
posed to aerosols from different water sources (spas, swim-
ming pools, hot tubs, metalworking fluid) (Embil et al.,
1997; Primm et al., 2004).
Mycobacteria and free-living amoebae thus share the
same ecosystem and their close interaction has been sus-
pected since the presence of mycobacteria within an amoe-
bal host was first reported in 1973 (Jadin, 1973). Further in
vitro studies not only demonstrated that mycobacteria were
able to enter and replicate within the trophozoites and cysts
of amoebae or other protozoa (Krishna Prasad & Gupta,
1978; Cirillo et al., 1997; Steinert et al., 1998; Strahl et al.,
2001; Taylor et al., 2003; Adekambi et al., 2006; Mura et al.,
2006; Whan et al., 2006; Thomas & McDonnell, 2007), but
also that amoeba-grown mycobacteria displayed increased
virulence in macrophage and mouse models of infection
(Cirillo et al., 1997). Their recovery in hospital water
networks has been strongly associated with the presence of
amoebae (Thomas et al., 2006). Moreover, pathogenic
strains of M. kansasii exhibit a better ability to grow in
Acanthamoeba castellanii than the nonpathogenic strains
colonizing the respiratory tract (Goy et al., 2007). The
mechanisms involved in the pathogenicity ofM. avium with
respect to macrophages and amoebae have been found to be
very similar (Danelishvili et al., 2007). These findings
suggest that mycobacteria, like legionellae, may take advan-
tage of amoebae, using them as a reservoir and as an
evolutionary niche for the development of virulence factors.
In contrast to legionellae and to some Chlamydia-like
organisms residing within the cytosol of the amoebal cysts,
mycobacteria are located within the double layers of the
cysts (Steinert et al., 1998). This evolutionary adaptation
may allow them to survive in a hostile environment such as
phagocytic human cells and to resist to high chlorine
concentrations or to the action of antibiotics (Miltner &
Bermudez, 2000; Adekambi et al., 2006; Thomas & McDon-
nell, 2007).
Bradyrhizobiaceae
Afipia spp. and Bosea spp. are recently discovered gram-
negative bacteria belonging to the class of Alphaproteobac-
teria (family: Bradyrhizobiaceae) and somehow related to
Table 4. Mycobacteria other than tuberculosis (MOTT): review of the most frequent agents of pneumonia
Mycobacterium species Pathogenic role in pneumonia References
M. avium intracellulare complex Most frequent cause of MOTT-associated respiratory
infection (variable presentation)
Olivier (1998), Field & Cowie (2006), Kim et al. (2008),
Parrish et al. (2008)
More frequent in HIV and immunocompromised patients Olivier (1998), Field & Cowie (2006), Parrish et al. (2008)
Cause of hypersensitivity pneumonia after exposure to hot
tubes
Embil et al. (1997), Field & Cowie (2006)
M. kansasii Pulmonary disease similar to M. tuberculosis. One of the
MOTT most frequently associated with pneumonia in both
immunocompetent and immunocompromised hosts
Evans et al. (1996a, b), Campo & Campo (1997), Taillard
et al. (2003), Maliwan & Zvetina (2005), Kim et al. (2008)
M. xenopi One of the MOTT most frequently associated with
pneumonia in both immunocompetent and
immunocompromised hosts
Juffermans et al. (1998), Faress et al. (2003), Andrejak
et al. (2007), Kim et al. (2008), van Ingen et al. (2008),
Marusic et al. (2009)
M. malmoense Most frequent cause of MOTT-associated respiratory
infection in the United Kingdom and Sweden, especially in
patients with underlying lung diseases. Cavitations are
often present
Research Committee of the British Thoracic Society
(2001), Henriques et al. (1994), Field & Cowie (2006)
M. chelonae Rare cause of fever and pneumonia in neutropenic cancer
patients
McWhinney et al. (1992), Levendoglu-Tugal et al. (1998),
Peres et al. (2009)
Rare cause of pneumonia in patients with oesophageal or
swallowing disorders
Burke & Ullian (1977), Hadjiliadis et al. (1999)
M. fortuitum Rare cause of pneumonia in patients with oesophageal or
swallowing disorders
Howard et al. (1991), Hadjiliadis et al. (1999)
Some cases of pneumonia reported mainly in
immunocompromised patients
Marchevsky et al. (1982), Ellis & Qadri (1993), Al Shaalan
et al. (1997), Abe et al. (1999), Miguez-Burbano et al.
(2006)
M. simae One of the MOTT most frequently isolated from respiratory
samples
Valero et al. (1995), El Sahly et al. (2002), Samra et al.
(2005)
Cause of pneumonia in patients with underlying pulmonary
diseases, rarely in AIDS patients
Bell et al. (1983), Huminer et al. (1993), Valero et al.
(1995), Maoz et al. (2008)
M. gordonae Frequently isolated from sputum, but rare cause of
respiratory infection
Eckburg et al. (2000), Thomsen et al. (2002), Field &
Cowie (2006)
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Brucella spp. and Bartonella spp. (Brenner et al., 1991; Das
et al., 1996). These Bradyrhizobiaceae are able to resist to
amoebal microbicidal effectors (Fig. 6). The original isola-
tion of Afipia spp. in clinical specimens such as lymph nodes
(Afipia felis) or bone biopsy (Afipia clevelandensis) raised the
question about their pathogenic role in human diseases,
particularly in cat scratch disease (English et al., 1988;
Brenner et al., 1991; Hall et al., 1991). However, subsequent
analyses identified Bartonella henselae as the causal agent of
this latter disease and the precise pathogenic role of Afipia
remained undetermined (Jerris & Regnery, 1996). These
bacteria were first detected in human respiratory samples
by Brenner et al. (1991), who described the new genus
Afipia. Drancourt et al. (1997) detected the presence of
antibodies against A. clevelandensis in 1.5% of sera tested in
the French national centre for rickettsial diseases and
postulated a cross-reactivity between this bacterium and
Brucella spp. or Yersinia spp., as about half of the cases had a
diagnosis of certain or probable brucellosis or yersiniosis.
However, about 15% of patients from this series were
diagnosed as having pneumonia (Drancourt et al., 1997).
The subsequent isolation of Afipia spp. and Bosea spp. in
hospital water supplies suggests a possible role in nosoco-
mial pneumonia (La Scola et al., 2000, 2002, 2003b, c;
Thomas et al., 2006, 2007). Sero-epidemiological analyses
revealed evidence of exposure to Afipia spp. and closely
related Alphaproteobacteria in 13% of patients with hospital-
acquired pneumonia, whereas no specific antibodies were
detected in healthy blood donors (Po 0.01) (La Scola et al.,
2002). The same strains were simultaneously detected in the
water supplies of the intensive care units where these
patients were staying. In another series of 30 patients in a
single intensive care unit in France, seroconversion to Afipia
spp. and Bosea spp. was documented in 17% and 20%
patients with VAP, respectively (La Scola et al., 2003b). No
alternative potential pathogen was documented in about
half of these cases. This study also reported a case of
pneumonia with detection of Bosea massiliensis by PCR in
bronchoalveolar lavage fluid associated with seroconversion
to the same microorganism (La Scola et al., 2003b). In
another analysis of 210 ICU patients with pneumonia, Bosea
spp. were detected in eight (3.8%) patients by culture, PCR
or serological testing (B. massiliensis and Bosea thiooxidans)
(Berger et al., 2006). However, evidence for recent infection
was documented in only one case and potential alternative
pathogens of pneumonia were isolated in all cases. All
patients but one had hospital-acquired pneumonia. Afipia
spp. were not detected in this population (Berger et al.,
2006). A Bosea and some other Alphaproteobacteria have also
been isolated from nasal swabs of hospitalized patients by
amoebal coculture, although their pathogenic role was
unclear (Greub et al., 2004b). Interestingly, the possible
implication of the Bradyrhizobiaceae in CAP has not yet
been investigated. Bosea strains have also been isolated from
environmental sources of water other than hospital net-
works such as river water or drinking water plants (Rapala
et al., 2006; Thomas et al., 2007) and Afipia spp. were the
most common bacterial species found in biofilms from a
dental unit water system in Baltimore (Singh et al., 2003).
The actual role of Bradyrhizobiaceae in RTIs thus remains
difficult to assess on the basis of serological diagnostic tools,
which lack sensitivity and specificity, and in the absence of
microbiological documentation in clinical specimens in
most cases.
Biodiversity of amoebae-resisting
microorganisms and perspectives for
further investigations
Free-living amoebae represent a widespread evolutionary
niche that may favour the selection of virulence traits in
intra-amoebal bacteria, enabling them to survive in other
phagocytic cells, including alveolar macrophages, which are
one a major line of immune defence against invading
pathogens. The examples of emerging pathogens provided
in this review probably represent only the tip of the iceberg,
and there is still a largely underestimated biodiversity of
amoebae-resisting bacteria, which may have acquired their
ability to cause diseases in humans by the development of
virulence traits during their intra-amoebal life. This huge
and so far unexplored biodiversity not only includes mem-
bers of the clade presented in this review, i.e. Legionella spp.,
Chlamydiae, Bradyrhizobiaceae and mycobacteria, but also
many other bacterial clades and giant viruses (Greub &
Raoult, 2004). At least one of the amoebae-resisting viruses
Fig. 6. Bosea sequanensis (arrows) within Acanthamoeba castellannii,
as seen by electron microscopy. Magnification  7000. Scale bar = 2 mm.
The inset is a drawing showing the limits of the amoeba (discontinuous
line) that contains about 19 bacteria (light grey); three bacteria that are
localized outside of the amoeba are highlighted in dark grey.
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discovered so far, the mimivirus, is also resistant to human
macrophages and may be involved in lower RTIs, as sug-
gested by clinical studies and by a well documented labora-
tory-acquired infection (see Box 1).
The research community should thus be aware of the
wide biodiversity of amoebae-resisting microorganisms in-
cluding novel Chlamydiae, new LLAP, some Bradyrhizobia-
ceae, the recently described novel waterborne mycobacterial
species and giant viruses. Although Parachlamydia and some
other amoebae-resisting Chlamydiae have already been
investigated for their pathogenic potential (Corsaro &
Greub, 2006; Greub, 2009), there is still an infinite and
exciting perspective for further investigations with regard to
the development of new diagnostic tools and the compre-
hension of the pathogenic roles and the cell biology of such
microorganisms.
Further investigations may be especially important given
the fact that the intra-amoebal environment may select
strains that are preferentially resistant to antibiotics and to
biocides. Such resistance may be due to the partial protection
conferred by amoebal trophozoites and cysts, or may result
from the acquisition of efflux mechanisms following exposi-
tion to heavy metals and other toxic compounds when inside
the amoebal host. The concomitant resistance to biocides
and chemical compounds that was first described in myco-
bacteria (Miltner & Bermudez, 2000), as well as the un-
expected resistance of Chlamydiae to quinolones (Maurin
et al., 2002; Casson & Greub, 2006; Goy & Greub, 2009), are
illustrations of the potential of amoebae-resisting bacteria to
select new virulence traits. Moreover, the intra-amoebal
environment likely represents an important niche for gene
exchange between intracellular pathogens, as exemplified by
the occurrence in Rickettsia bellii (Ogata et al., 2006) and in
P. amoebophila (Greub et al., 2004a) of similar genes encod-
ing a putative F-like conjugative DNA transfer system. Such
gene exchanges not only occur between different bacterial
clades, but also likely take place with giant amoebae-resisting
viruses and with the genomic content of the amoebal host
itself, explaining the relatively large genomes of amoebae-
resisting microorganisms.
Box 1. Mimivirus, a giant virus likely involved in lower respiratory tract infections
Mimivirus (Mimiviridae) is a double-stranded DNA virus belonging to the nucleocytoplasmic large DNA viruses (NCLDV). Initially discovered within
free-living amoebae recovered by amoebal enrichment from a cooling tower during the investigation of an outbreak of community-acquired
pneumonia in Bradford (UK), this microorganism was first considered to be a gram-positive bacterial coccus (La Scola et al., 2003a). However,
electron microscopy suggested that it was a giant virus of about 400 nm in diameter and subsequent studies unequivocally confirmed its affiliation
within the NCLDV, which also includes the Iridoviridae, the Phycodnaviridae, the Asfarviridae and the Poxviridae (Koonin, 2005). Its genome of about
1.18 Mb encodes for about 911 ORFs and six tRNA genes (Raoult et al., 2004).
As this virus was shown to grow well within Acanthamoeba polyphaga (La Scola et al., 2003a), its possible resistance to destruction by human
macrophages was readily suspected and confirmed by Ghigo et al. (2008). Thus, mimivirus was shown to selectively enter within human
macrophages and not into epithelial cells (Ghigo et al., 2008). More importantly, entry occurred by phagocytosis (as demonstrated by its inhibition by
overexpression of a dominant-negative form of a regulator of phagocytosis, dynamin-II), and was followed by efficient exponential replication (Ghigo
et al., 2008). This further supported the paradigm that intra-amoebal pathogens may also be resistant to macrophages and suggested its possible
pathogenic role towards humans.
Some clinical studies have further supported the possible role of mimivirus in lower respiratory tract infections. Thus, 36 (9.7%) patients with
community-acquired pneumonia exhibited antibody reactivity against mimivirus as compared with 12 (2.3%) of 511 healthy controls (Po 0.01) (La
Scola et al., 2005). In addition, serologic evidence of mimivirus infection was also observed in five (19.2%) of 26 intensive care unit patients, whereas
none of the 50 control patients were seropositive for mimivirus (Po 0.01). More importantly, mimivirus DNA was detected in a bronchoalveolar
lavage sample from a 60-year-old comatose patient who presented two episodes of hospital-acquired pneumonia during hospitalization in the
intensive care unit (La Scola et al., 2005). Moreover, in another study, patients exhibiting antimimivirus antibodies had longer durations of mechanical
ventilation and intensive-care unit stay, with median excesses of 7 and 10 days, respectively (Vincent et al., 2009). However, when testing 496
different pneumonia patients with two different real-time PCRs, other investigators failed to identify any case of mimivirus (Dare et al., 2008). This
discrepancy might potentially be due to the possible occurrence of mimivirus-like strains, which cross-react with mimivirus but exhibit some
differences in the region of the viral helicase and thiol-oxidoreductase genes used as PCR targets, preventing their detection using this method (Dare
et al., 2008). It is noteworthy that the pathogenic role of mimivirus has been clearly demonstrated by an accidental exposure of a laboratory
technician to mimivirus (Raoult et al., 2006). Besides strongly supporting the pathogenicity of mimivirus, this laboratory-acquired infection highlights
the importance of cautious manipulation of such emerging potential pathogens, especially given the current absence of antivirals that are efficient
against such giant viruses.
Finally, the pathogenic role of mimivirus was further supported by a mouse model of infection (Khan et al., 2007). Thus, mice inoculated through the
intracardiac route presented pneumonia similar to viral pneumonia due to measles, smallpox and rubella. Interestingly, a virophage called Sputnik
was found closely associated with a new giant virus also belonging to the Mimiviridae (La Scola et al., 2008). Both the giant virus and the virophage
may replicate efficiently within Acanthamoeba amoebae (Fig. 7). Whether this small icosahedral virus may modify the pathogenicity of the
Mimiviridae remains to be investigated.
In conclusion, humans are commonly exposed to mimivirus or cross-reacting agents and mimivirus was pathogenic at least towards humans following
accidental laboratory exposure and to mice following intravenous challenge. Moreover, this amoebae-resisting virus (or a related cross-reactive
species) should be considered as an emerging agent of both nosocomial and community-acquired pneumonia and clearly merits further study.
FEMS Microbiol Rev 34 (2010) 260–280c 2010 Federation of European Microbiological Societies
Published by Blackwell Publishing Ltd. All rights reserved
272 F. Lamoth & G. Greub
Conclusion
Amoebae and intra-amoebal microorganisms have coe-
volved for millions of years and have generated a wide
biodiversity of microorganisms that are likely to be able to
resist both the phagocytic machinery of amoebae and hu-
manmacrophages. Thus, the amoebal evolutionary crib may
have produced a widespread biodiversity of potential patho-
genic species that remain to be discovered. The isolation of
these fastidious bacteria and their species identification by
culture-based methods, such as amoebal coculture and the
amoebal enrichment, as well as the development of mole-
cular methods for their detection in clinical samples, are
warranted for a better assessment of their actual role in
human diseases such as pneumonia, which remains a major
cause of morbidity and mortality in the world. A better
comprehensive approach of the interactions between free-
living amoebae and amoebae-resisting organisms may give
further insights into the mechanisms of pathogenicity of
microorganisms and their mode of acquisition of resistance
to environmental aggressions, such as phagocytosis by
amoebae and macrophages, biocides or chemical com-
pounds, with potential implications for therapeutic ap-
proaches.
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